Jak2V617F driven myeloproliferative neoplasm occurs independently of interleukin-3 receptor beta common signaling

Haematologica. 2016 Mar;101(3):e77-80. doi: 10.3324/haematol.2015.136705. Epub 2015 Nov 20.
No abstract available

Keywords: chronic myeloproliferative disorders; cytokine signaling; hematopoietic stem cell.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Marrow / drug effects
  • Bone Marrow / immunology
  • Bone Marrow / pathology
  • Gene Expression Regulation, Neoplastic*
  • Hematologic Neoplasms / genetics
  • Hematologic Neoplasms / immunology*
  • Hematologic Neoplasms / pathology
  • Humans
  • Interleukin-3 / genetics
  • Interleukin-3 / immunology*
  • Janus Kinase 2 / genetics
  • Janus Kinase 2 / immunology*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Mutation
  • Myeloproliferative Disorders / genetics
  • Myeloproliferative Disorders / immunology*
  • Myeloproliferative Disorders / pathology
  • Receptors, Interleukin-3 / genetics
  • Receptors, Interleukin-3 / immunology*
  • STAT5 Transcription Factor / genetics
  • STAT5 Transcription Factor / immunology
  • Signal Transduction
  • Thrombopoietin / pharmacology

Substances

  • Interleukin-3
  • Receptors, Interleukin-3
  • STAT5 Transcription Factor
  • Thrombopoietin
  • Jak2 protein, mouse
  • Janus Kinase 2